Acadia Pharmaceuticals generated $576 million in first-half 2026 revenues, up 13% year-over-year, and raised its full-year 2026 guidance to $1.24-$1.30 billion. Nuplazid sales grew 7% to $350.1 million with patent protection until February 2038, while Daybue sales jumped 25% to $226 million, driven by the new STIX formulation and EU approval for Rett syndrome treatment. However, ACAD shares have underperformed the industry by 27.3% year-to-date and face increasing competition from rivals like Axsome and Neurogene.

Axsome Therapeutics' Auvelity drug is expanding beyond major depressive disorder into Alzheimer's agitation treatment, with Q2 sales reaching $180.3 million (up 51% YoY) and new patient starts among seniors jumping 126% post-launch. The company projects Auvelity could eventually generate $8 billion in annual peak sales, with additional commercial products and pipeline candidates potentially transforming Axsome into a major neuroscience pharmaceutical company by 2030.

Four central nervous system (CNS) pharmaceutical companies—Axsome Therapeutics, Neurocrine Biosciences, Alkermes, and Acadia Pharmaceuticals—are highlighted as relevant investment opportunities ahead of World Mental Health Day. All four companies carry a Zacks Rank #3 (Hold) rating and have strong CNS portfolios with meaningful revenue growth in H1 2026, supported by expanding pipelines addressing psychiatric and neurological disorders.

Axsome Therapeutics reported Q2 2026 earnings that met EPS estimates but missed revenue expectations at $218.4M vs. $225M consensus. While lead drug Auvelity drove strong 51% YoY sales growth to $180.3M and Sunosi performed well, newest drug Symbravo significantly underperformed at $2.3M against $7.2M estimates. Post-earnings, analyst estimates have trended downward, and the stock has underperformed the S&P 500 by 3.7% over the past month.

PVG Asset Management, a significant shareholder of Anavex Life Sciences, has launched a proxy contest calling for complete board reconstitution, citing operational failures, governance issues, and failure to deliver shareholder value. PVG has nominated six biotechnology-experienced directors to replace the current board, criticizing the company's underperformance relative to peers, delayed clinical trials for its lead drug blarcamesine, significant executive departures, and recent stock decline amid broader biotech sector gains.

Axsome Therapeutics has dosed the first patient in the phase III SUMMIT study evaluating AXS-05 for smoking cessation. The randomized, double-blind, placebo-controlled trial will compare AXS-05 against bupropion and placebo over 12 weeks, with smoking abstinence as the primary endpoint. Axsome's lead drug Auvelity continues to drive strong revenue growth, generating $333 million in H1 2026 (up 54.2% YoY), while the company's diversified portfolio includes Sunosi and newly launched Symbravo.

Axsome Therapeutics announced it will report Q2 2026 financial results on August 10, 2026, followed by a management conference call at 8:00 a.m. ET. The company is advancing its CNS disorder treatment portfolio with FDA-approved products including SUNOSI, AUVELITY, and SYMBRAVO, while progressing multiple clinical trials including Phase 3 FOCUS-2 and FOCUS-3 trials for solriamfetol in pediatric and adolescent ADHD patients.

Three biotech companies—Moderna, Revolution Medicines, and Axsome Therapeutics—significantly outperformed the S&P 500 in the first half of 2026 with double- and triple-digit gains. While Moderna faces expected pullback despite flu vaccine approval prospects, and Revolution Medicines shows modest upside, Wall Street expects Axsome to climb another 13% due to recent drug approvals and strong pipeline progress.

Axsome Therapeutics has experienced significant growth with its CNS disorder treatments, including recently approved drugs Auvelity for Alzheimer's agitation and Symbravo for migraines. While the stock has climbed 220% over three years and has strong revenue growth, the article cautions that reaching millionaire status from a single stock investment is unrealistic, recommending instead a diversified portfolio approach.

Axsome Therapeutics announced the initiation of the FOCUS-3 Phase 3 trial evaluating solriamfetol for treating ADHD in adolescents aged 12-17. The randomized, double-blind, placebo-controlled trial will enroll approximately 468 patients across multiple centers over 6 weeks, with the primary endpoint measuring changes in ADHD Rating Scale scores.

Hypercharge Networks Corp. announced the grant of 2,630,000 stock options at an exercise price of $0.08 and 1,115,464 deferred share units to directors, officers, employees, and consultants. The company also announced it was named co-winner of the Canada Growth Cup and grew its total charging ports by over 45% through the acquisition of Eddie from AXSO, adding over 2,700 ports under management.

The article highlights three biotech companies with strong growth potential over the next decade: Madrigal Pharmaceuticals, which has the first-approved MASH treatment with significant market opportunity; Axsome Therapeutics, which is expanding its depression medicine Auvelity into Alzheimer's disease treatment; and Kailera Therapeutics, a newly public company developing weight-loss medicines in a fast-growing market. All three operate in high-need therapeutic areas with promising pipelines.